Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

The oncologist - 1 Jan 2011

Deenen Maarten J, Cats Annemieke, Beijnen Jos H, Schellens Jan H M

Abstract excerpt

Equivalent drug doses in anticancer chemotherapy may lead to wide interpatient variability in drug response reflected by differences in treatment response or in severity of adverse drug reactions. Differences in the pharmacokinetic (PK) and pharmacodynamic (PD) behavior of a drug contribute to variation in treatment outcome among patients. An important factor responsible for this variability is genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Share to ATP-Binding Cassette Transporters

Share to Enzyme Inhibitors

Share to Precision Medicine

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 21632461
DOI: 10.1634/theoncologist.2010-0259
PMCID: PMC3228220

Genes

ABCB1
ABCG2
BLMH
CDA
DPYD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.PMID 21632461Read ↗

Part 1: background, methodology, and clinical adoption of pharmacogenetics.Semantic proximity Read ↗

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.Semantic proximity Read ↗

Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Semantic proximity Read ↗

Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.Semantic proximity Read ↗

Pharmacogenetics of Drugs Used in the Treatment of CancersSemantic proximity Read ↗

Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.Semantic proximity Read ↗

Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug DevelopmentSemantic proximity Read ↗

Pharmacogenetics and pharmacogenomics of anticancer agents.Semantic proximity Read ↗

Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.Semantic proximity Read ↗

Pharmacogenomics in cancer therapy: is host genome variability important?Semantic proximity Read ↗

Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical ImplicationsSemantic proximity Read ↗

[Pharmacogenetics of anticancer drugs].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.